Just four months after Simcere Zaiming's founding, the organization is sharing details on targets and technologies, including two oral presentations
BOSTON, April 13, 2023 /PRNewswire/ -- Simcere Zaiming (Company), a pharmaceutical company focused on developing drugs to address unmet clinical needs for cancer patients around the globe, and subsidiary of Simcere Pharmaceutical Group Limited (2096.HK) (Simcere), a global pharmaceutical company, today announced two oral and six poster presentations will be presented on the Company's preclinical programs at the 2023 American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-19, 2023, in Orlando, FL. The AACR annual meeting is one of the most influential oncology conferences of the year and attracts tens of thousands of scientists and clinical experts to share and discuss the latest progress in basic research, translational research, clinical research and prevention research in the field of oncology. Today's announcement marks a significant milestone for the company as it will be the first time Simcere Zaiming will participate in an international academic conference as an independent oncology entity with multiple studies, including on-site oral presentations. The eight studies cover several targets including SMARCA2, CBL-b, Polθ, SOS1, MUC17, USP1, SIRPα, GPRC5D, and involve multiple novel technologies such as targeted protein degradation, mutant fusion proteins, bispecific T engager and others. Session Type: Minisymposium
Session Category: Experimental and Molecular Therapeutics
Session Title: Innovative Therapeutic Approaches
Session Date/Time: Sunday Apr 16, 2023 3:00 PM - 5:00 PM
Abstract Presentation Number: 1137
Presenter: Dr. Zhengtao Li, Vice President, Simcere Zaiming
Targeting the "synthetic lethal" partner proteins SMARCA2/4 (human chromatin SWI/SNF- Related, Matrix-Associated, actin-dependent regulatory factor subfamily A member 2 and 4), SCR-9140 selectively degrades SMARCA2 to precisely kill SMARCA4-deficient tumorsSMARCA4-deficient tumors in preclinical studies while preventing damage to normal cells, thus exhibiting strong antitumor efficacy and favorable safety profile. Title: Identification of the selective CBL-b inhibitors which effectively prevent T cells from exhaustion and demonstrate synergistic anti-tumor activity in combination with an anti-PD1 antibody Session Title: Immune Checkpoints at Tumor Beds Session Date/Time: Monday Apr 17, 2023 2:30 PM - 4:30 PM
Abstract Presentation Number: 3474
Presenter: Dr. Tamas Oravecz, Senior Vice President, Chief Scientific Officer, Simcere Zaiming
Title: Identification of SS008871, a novel Polθ inhibitor that effectively inhibits tumors with homologous recombination deficiency in vitro and in vivo Session Title: Experimental and Molecular Therapeutics, Novel Antitumor Agents 2
Session Date and Time: Sunday Apr 16, 1:30 PM – 5:00 PM
Location: Poster Section 18
DNA polymerase θ (Polθ) is a key enzyme for DNA double-strand break repair and cell survival in homologous recombination-deficient tumors, and it is also a potential synthetic lethal new therapeutic target. The small molecule inhibitor of Pol θ, SS008871, has shown significant anti-tumor effect and good safety in various preclinical models. Session Title: Oncogenes and Tumor Suppressor, Genes as Targets for Therapy 2 Session Date and Time: Monday, Apr 17, 9 AM – 12:30 PM
Location: Poster Section 20
The most common oncogene, KRAS, was once regarded as the most difficult drug target, and there was a large unmet clinical need. SCR-8388 is a selective SOS 1 protein inhibitor that acts on the upstream pathway of KRAS and prevents KRAS activation. Preclinical studies have shown that SCR-8388 can significantly inhibit the growth of KRAS mutant tumors in both in vitro and in vivo models, and has a synergistic effect with EGFR antagonists. Session Title: Immunology, Therapeutic Antibodies 1
Session Date and Time: Monday Apr 17, 9:00 AM - 12:30 PM
Location: Poster Section 25
Title: A novel T cell engager targeting BCMA and GPRC5D showed promising preclinical activity with low toxic risk for multiple myeloma treatment Session Title: Immunology, Therapeutic Antibodies 1
Session Date and Time: Monday Apr 17, 9:00 AM - 12:30 PM
Location: Poster Section 25
SCR-8572, a T-cell engager developed against two specific targets in multiple myeloma, BCMA and GPRC5D, demonstrated potent tumor-killing effects in preclinical in vitro and in vivo models, with preliminary good safety results. It is expected to become a candidate drug for clinical development. Title: Identification of SP-002, a highly selective USP1 inhibitorUSP1 inhibitor effectively inhibits HRD tumor growth and displays low hematotoxicity risk Session Title: Experimental and Molecular Therapeutics, DNA Repair / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes / Others Session Date and Time: Wednesday Apr 19, 9:00 AM - 12:30 PM
Location: Poster Section 18
Title: Generation of a mutant SIRPa fusion protein with highly-improved affinity and favorable safety profile
Session Title: Immunology, Immune Checkpoints
Session Date and Time: Wednesday Apr 19, 9:00 AM - 12:30 PM
Location: Poster Section 23
Simcere Zaiming is a pharmaceutical company specializing in oncology, and a subsidiary of Simcere Pharmaceutical Group Limited, that focuses on the R&D, production and commercialization of innovative cancer therapeutics. The company was formed in 2023 and is committed to solving unmet clinical needs for cancer patients in China and around the world by developing breakthrough treatments. Simcere Zaiming has an innovative R&D pipeline with differentiated clinical value, among which 15 assets are currently in clinical trials. In addition to the company's R&D portfolio, Simcere Zaiming is marketing three innovative drugs, COSELA®, Endostar®, and Envafolimab®. By collaborating with partners globally, Simcere Zaiming strives to bring potentially new innovative therapeutics to cancer patients worldwide. Simcere Pharmaceutical Group Limited (2096.HK) is an innovation and R&D-driven pharmaceutical company. The Company focuses on three therapeutic areas, oncology, central nervous system and autoimmune diseases, with a forward-looking vision toward disease areas that may have significant clinical needs in the future, aiming to achieve the mission of "providing today's patients with medicines of the future." Leveraging its R&D capability and commercialization excellence, Simcere has built a market-leading product portfolio in China. Its vigorous in-house R&D efforts and extensive R&D and commercial stage collaborations have made it a strategic alliance partner with world-leading innovative companies and research institutes. For more information, please visit: http://en.simcere.com/
Director, Corporate Communications & Public Affairs